Heme

Advertisement
Keightley Amen, BA, ELSSickle Cell Disease | June 18, 2025
Evidence was presented at EHA2025 that the agent improves RBC health and blood flow in patients.
Keightley Amen, BA, ELSSickle Cell Disease | June 17, 2025
Two cases of patients with SCD and history of delayed hemolytic transfusion reaction were presented at EHA2025.
Keightley Amen, BA, ELSSickle Cell Disease | June 17, 2025
The analysis was an assessment of 15-year follow-up data from the CLIMB study and was presented at EHA2025.
Andrew MorenoMPN | June 16, 2025
The study data presented at EHA2025 were from patients who had disease resistant to prior therapy or intolerance to therapy.
Andrew MorenoMyelofibrosis | June 16, 2025
The FDA previously granted Orphan Drug Designation to nuvisertib for use in myelofibrosis in May 2022.
Melissa BadamoSickle Cell Disease | June 13, 2025
Vivien Sheehan, MD, explained how a novel assay can guide personalized therapeutic approaches for sickle cell disease.
Melissa BadamoSickle Cell Disease | June 11, 2025
Rilzabrutinib significantly decreased spleen weight and reduced inflammation in mice with homozygous sickle cell genotype.
Melissa BadamoSickle Cell Disease | June 10, 2025
MIRCA is a device designed to assess the flexibility of red blood cells of patients with sickle cell disease.
Robert ZadottiMDS | June 6, 2025
The study will assess the overall response to olutasidenib plus azacitidine in higher-risk MDS, CMML, and advanced MPNs.
Robert ZadottiHematology | June 6, 2025
In a study, patients with T2DM and MGUS who used GLP-1 agonists were observed over 10 years to have reduced MM rates.
Andrew MorenoHematology | June 5, 2025
Arm D of the SEQUOIA trial evaluated the combo in patients with either del(17p) or TP53 mutation, both mutations, or neither.
Nichole TuckerITP | June 6, 2025
The results are reported from an international cohort and support adding the agent to plasma exchange and immunosuppression.
Andrew MorenoMyelofibrosis | May 30, 2025
MANIFEST-2 compares pelabresib plus ruxolitinib with placebo plus ruxolitinib for JAK-inhibitor-naive disease.
Melissa BadamoTTP | May 30, 2025
In a phase 3 study, patients who received recombinant ADAMTS13 did not experience acute TTP events during prophylaxis.
Melissa BadamoAnemia | May 29, 2025
Iron deficiency anemia was associated with 39% increased odds of stroke, independent of the risk factors for stroke.
Melissa BadamoEssential Thrombocythemia | May 27, 2025
While cytoreductive drugs did not reduce thrombosis risk, interferon significantly improved myelofibrosis-free survival.
Andrew MorenoHemophilia | May 20, 2025
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
Andrew MorenoPNH | May 19, 2025
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
Andrew MorenoVTE | May 16, 2025
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
Andrew MorenoAnemia | May 16, 2025
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
Advertisement